Ascendia

  MARKET NEWS

Olema Oncology Announces New Clinical Trial Collaboration & Supply Agreement
PTC Therapeutics Enters Global License & Collaboration Agreement With Novartis 
Ocular Therapeutix Announces More Than 300 Subjects Randomized in SOL-1
XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty & Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio
Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS
Sana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus Erythematosus
Lin BioScience Receives FDA Fast Track Designation For LBS-007
Marinomed Biotech AG Signs Agreement for Sale of Carragelose Business to Unither Pharmaceuticals
Nutriband Receives Patent Notice of Publication for its Abuse Deterrent Transdermal Technology
NovelMed Receives FDA IND Approval for the First Anti-Bb Alternative Pathway Blocker for Treating Primary Immunoglobulin A Nephropathy (IgAN): A Renal Disorder

  EXPERT CONTENT & RESOURCES

 

BASF Article - Should Developers Choose a Cosmetic or Pharmaceutical-Grade Excipient?

BASF Article - Should Developers Choose a Cosmetic or Pharmaceutical-Grade Excipient?

As regulations continue to change around cosmetic and pharmaceutical-grade excipients, the pharmaceutical industry has choices to make when investing in quality, risk, and public safety.

ALBA SUCCESS CASE

Container Selection for a Highly Sensitive Drug Product: A Success Story

For new drug products, it is essential that pharmaceutical companies utilize the experience of container suppliers as early as possible.

On-Demand Presentation: High Concentration Protein Suspensions: A Bevacizumab Case Study (>400 mg/mL)

On-Demand Presentation: High Concentration Protein Suspensions: A Bevacizumab Case Study (>400 mg/mL)

Dr. Cindy Chung presents a case study demonstrating the development of high concentration bevacizumab suspension at up to 400 mg/mL for suitable subcutaneous delivery of the monoclonal antibody (mAb) therapy. Watch the presentation now to learn more.

  FEATURED EDITORIAL

  COMPANY PROFILE

Douglas CDMO, based in New Zealand, has a history dating back to 1967. We offer end-to-end integrated drug development services, specializing in high-potency small molecule softgels, liquids, semi-solids, new chemical entities (NCEs), and branded generics. Our capabilities extend to manufacturing prescription drugs across key therapeutic areas, including oncology, dermatology, the central nervous system, and immunity. Working with clients across the globe, we pride ourselves on delivering superior quality and excellent service, ensuring our partners achieve successful, timely outcomes. Our strategic location in Auckland, New Zealand offers our global customers with tax incentives and the ability to start first in human trials quicker than many other jurisdictions due to a streamlined regulatory process. Click here for more.

  WHITEPAPERS & WEBINARS

ARTICLE - A New Framework for Identifying Nitrosamine Risks & Efficiently Derisking Products

ARTICLE - A New Framework for Identifying Nitrosamine Risks & Efficiently Derisking Products

A clear standard for identifying APIs susceptible to Nitrosamine Drug Substance-Related Impurities (NDSRI) formation has been elusive—until now. Adare’s team of nitrosamine experts have developed a straightforward framework that simplifies the identification of at-risk APIs. Discover how this innovative approach …

WHITEPAPER - Unlock the Secrets of Spray Drying for Sticky APIs

WHITEPAPER - Unlock the Secrets of Spray Drying for Sticky APIs

It is widely reported that 40% of New Chemical Entities (NCEs) in the pharmaceutical industry are poorly soluble, leading to inadequate bioavailablity. Spray drying is one of the most promising particle engineering technologies used to overcome solubility issues in active …

WHITEPAPER - Concept to Commercialization: The Role of CDMOs in Driving Innovation Through Phase-Appropriate Technology Transfers

WHITEPAPER - Concept to Commercialization: The Role of CDMOs in Driving Innovation Through Phase-Appropriate Technology Transfers

CDMOs are emerging as critical drivers of innovation within the pharmaceutical and biotech industries. As the pharmaceutical industry continues to evolve, we can expect to see CDMOs play an increasingly important role in drug development and manufacturing. Many companies within …

CASE STUDY - Overcoming Barriers to Patient Adherence With A Novel Dosage Form

CASE STUDY - Overcoming Barriers to Patient Adherence With A Novel Dosage Form

When a mid-sized pharmaceutical company asked Adare to make a version of their drug that was more convenient for patients with tremors or swallowing difficulties, our experts created a sprinkle formulation of the drug. In this CPHI Award-winning case study, …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

December 11 – ODT/Fast Dissolve
December 18 – Lyophilization Manufacturing